Antimicrobial Agents and Chemotherapy
Antimicrobial Agents and Chemotherapy
4 years ago

Evaluation of PK/PD model-based optimized combination regimens against multidrug-resistant Pseudomonas aeruginosa in a murine thigh infection model using humanized dosing schemes.

Landersdorfer, Nation, Wang, Bulitta, Yadav
We previously optimized imipenem and tobramycin combination regimens against a double-resistant clinical P. aeruginosa isolate using in vitro infection models, mechanism-based PK/PD modeling (MBM) and Monte Carlo simulations. The current study aimed to evaluate these regimens in a neutropenic murine thigh infection model and to characterize the time-course of bacterial killing and regrowth via MBM. We studied monotherapies and combinations of imipenem with tobramycin in vivo against the double-resistant clinical P. aeruginosa isolate using humanized dosing schemes. Viable count profiles of total and resistant populations were quantified over 24h. Tobramycin monotherapy (7 mg/kg q24h as 0.5h infusions) was ineffective. Imipenem monotherapies (continuous infusion of 4 or 5 g/day with 1 g loading dose) yielded 2.47 and 2.57 log10 CFU/thigh killing at 6h. At 24h, imipenem 4 g/day led to regrowth up to the initial inoculum (4.79±0.26 log10 CFU/thigh), whereas imipenem 5 g/day displayed 1.75 log10 killing versus the initial inoculum. The combinations (i.e. imipenem 4 or 5 g/day plus tobramycin) provided a clear benefit with bacterial killing of ≥2.51 and ≥1.50 log10 CFU/thigh compared to the respective most active monotherapy at 24h. No colonies were detected on 3×MIC agar plates for combinations, whereas increased resistance (at 3×MIC) emerged for monotherapies (except imipenem 5 g/day). MBM suggested tobramycin considerably enhanced the imipenem target site concentration up to 2.6-fold. The combination regimens, rationally optimized via a translational modeling approach, demonstrated substantially enhanced bacterial killing and suppression of regrowth in vivo against a double-resistant isolate, and are therefore promising for future clinical evaluation.

Publisher URL: http://doi.org/10.1128/AAC.01268-17

DOI: 10.1128/AAC.01268-17

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.